Tempest Therapeutics Inc 2026年季度报告

☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIESEXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIESEXCHANGE ACT OF 1934 For the transition period fromto.Commission File No. 001-35890 Tempest Therapeutics, Inc.(Exact Name of Registrant as Specified in its Charter) (Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during thepreceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past90 days. Yes☒No☐Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerginggrowth company. See the definitions of “large accelerated filer,” accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 ofthe Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revisedfinancial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).Yes☐No☒ INDEX TO FORM 10-Q Special Note Regarding Forward-Looking Statements3PART I — FINANCIAL INFORMATION5Item 1.Financial Statements (unaudited):5Condensed Consolidated Balance Sheets as of March 31, 2026 and December 31, 20255Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2026 and20256Condensed Consolidated Statements of Stockholders’ Equity for the Three Months Ended March 31,2026 and 20257Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2026 and20258Notes to Condensed Consolidated Financial Statements9Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations24Item 3.Quantitative and Qualitative Disclosures About Market Risk33Item 4.Controls and Procedures33 PART II — OTHER INFORMATION Item 1.Legal Proceedings34Item 1A.Risk Factors34Item 2.Unregistered Sales of Equity Securities and Use of Proceeds35Item 3.Defaults Upon Senior Securities35Item 4.Mine Safety Disclosures35Item 5.Other Information35Item 6.Exhibits36Signatures SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements (including within the meaning of Section 21E of theSecurities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended (the “Securities Act”))about us and our industry that involve substantial risks and uncertainties. These statements may discuss goals, intentions andexpectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs ofour management, as well as assumptions made by, and information currently available to, our management. Forward-lookingstatements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, andinclude words such as “may,” “will,” “should,” “would,” “could,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,”“intend,” and other similar expressions. Statements that are not historical facts are forward-looking statements. Forward-lookingstatements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of futureperformance. Actual results could differ materially from those contained in any forward-looking statement as a result of variousfactors, including, without limitation: whether we are successful in implementing our strategic review (which includes our plans toadvance our clinical-stage programs and maximize stockholder value); our strategies, prospects, plans, expectations or objectivesfor future operations; the progress, scope or timing of the development of our product candidates; unexpected safety or efficacydata observed during preclinical or clinical trials; the possibility that results from prior clinical trials and preclinical studies may notnecessarily be predictive of future results; past results may not be indicative of future results; clinical trial site activation orenrollment rates that are lower than expected; loss of key personnel;